ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has announced a Board of Directors meeting scheduled for November 14, 2026. The primary agenda is to consider and approve the standalone and consolidated un-audited financial results for the quarter and half-year ended September 30, 2026. In line with SEBI regulations, the trading window will be closed from October 1, 2026, until 48 hours after the results are made public.

ANG Lifesciences India Limited announced the re-appointment of Ms. Chetna as an Independent Director. The shareholders approved her reappointment for a second term of five years, effective from October 12, 2026, to October 11, 2031. Ms. Chetna brings extensive experience in corporate law, securities law, SEBI compliances, financial management, accounts, and taxation. She holds an L.L.B., is a Company Secretary, and has an MBA in Finance. She is also registered in the Independent Director Databank. The company confirmed there are no relationships between Ms. Chetna and other Directors or Key Managerial Personnel, and she is not debarred from holding a director's office by any regulatory authority.

ANG Lifesciences India Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The window will be shut from October 1, 2026, until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading. The specific date for the board meeting to consider these financial results will be communicated separately.

ANG Lifesciences India Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the notice for its 20th Annual General Meeting (AGM). The AGM is scheduled for September 30, 2026, and will be conducted via video conferencing. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, the re-appointment of Mr. Rohit Mittal as a director retiring by rotation, ratification of Cost Auditor remuneration for FY27, and the re-appointment of Mrs. Chetna as an Independent Director. The company has also confirmed that the Annual Report has been uploaded to its website.

ANG Lifesciences India Ltd has announced its 20th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 12:00 PM. The meeting will be conducted through Video Conferencing (VC)/ Other Audiovisual Means (OAVM) in compliance with circulars from the Ministry of Corporate Affairs and SEBI. Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. Rohit Mittal as a director, ratification of cost auditor remuneration for FY 2026-27, and the re-appointment of Mrs. Chetna as an Independent Director for a second five-year term.

ANG Lifesciences India Ltd has announced that its 20th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 12:00 PM. The meeting will be conducted through Video Conference (VC) or Other Audio Visual Means (OAVM), in compliance with relevant circulars from the Ministry of Corporate Affairs (MCA) and SEBI. This intimation serves as a formal notification to shareholders for their information and record.

ANG Lifesciences India Ltd's Board of Directors met on September 7, 2026, approving key corporate actions. The board appointed M/s Shreya Sahu & Associates as the Cost Auditor for FY 2026-27 and approved the Board's report for FY 2025-26. The 20th Annual General Meeting is scheduled for September 30, 2026, with a book closure period from September 24 to September 30, 2026. The board also approved the re-appointment of Mr. Rohit Mittal and Mrs. Chetna as an Independent Director for a second five-year term, subject to shareholder approval.

ANG Lifesciences India Ltd announced its standalone and consolidated un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 14, 2026. A limited review report for the same period was also presented. The company operates in Pharmaceuticals and Printing & Packaging segments. Detailed financial figures for revenue, expenses, and profit/loss for both standalone and consolidated statements were provided, along with segment-wise performance.

ANG Lifesciences India Ltd has announced the submission of its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results, along with the Limited Review Report, during a meeting held on August 14, 2026. The financial results were reviewed by the Audit Committee prior to board approval. The filing indicates that the results pertain to the first quarter of the fiscal year 2027.

ANG Lifesciences India Ltd has announced a Board of Directors meeting scheduled for August 14, 2026. The primary agenda is to consider and approve the standalone and consolidated un-audited financial results for the quarter ended June 30, 2026. The company has also informed that the trading window for its securities will remain closed from July 1, 2026, until 48 hours after the results are made public.